Business Context and Reporting Period
This Form 8-K Current Report from OptimizeRx Corporation (OPRX) covers events occurring on June 9, 2026, specifically the results of the Company's 2026 Annual Meeting of Shareholders. The Company is incorporated in Nevada and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metrics.
Material Changes and Shareholder Votes
Shareholders voted on five proposals at the Annual Meeting. The record date was April 10, 2026, with 18,765,075 shares outstanding.
- Director Elections: All seven nominees were elected to the Board of Directors.
- Executive Compensation: The advisory vote on executive compensation was approved (11,660,549 votes in favor vs. 895,095 against).
- Equity Plan Amendment (Share Increase): Shareholders approved an amendment to increase the number of shares available for awards under the 2021 Equity Incentive Plan by 1,000,000 shares, bringing the total to 5,450,000 shares.
- Equity Plan Amendment (Evergreen Provision): Shareholders rejected the proposal to adopt an "evergreen" provision for automatic annual increases in available shares (5,627,324 votes in favor vs. 7,001,699 against).
- Auditor Ratification: Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The primary corporate action noted is the successful increase in the equity pool size, while the failure to pass the evergreen provision indicates shareholder preference for periodic review of equity grants rather than automatic annual increases.
Investor Verification Checklist
- Verify the impact of the rejected "evergreen" provision on future equity dilution and the Company's ability to attract talent without annual shareholder approval.
- Review the full Proxy Statement (filed April 30, 2026) for details on the 2021 Equity Incentive Plan terms and executive compensation specifics.
- Confirm the current number of shares reserved for the Equity Plan is now 5,450,000 following the approved amendment.
- Check subsequent filings for the Company's 2026 financial results, as this 8-K does not include financial statements.